SINOVAC BIOTECH LTD
SVANasdaq
$6.47
End-of-day
Price
No price history ingested.
Key statistics
Market Cap
$464.9M
Enterprise Value
-$5.0B
P/E
—
P/S
1.2
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
-120.7%
Dividend Yield
850.1%
Revenue (TTM)
$386.0M
Net Income (TTM)
—
Free Cash Flow (TTM)
-$561.1M
Gross Margin
67.9%
Operating Margin
-127.0%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
0.1
Net Cash
$5.5B
Return 1Y
0.0%
Company profile
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
- CEO
- N/A
- Headquarters
- Ontario
- Website
- N/A
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $510.6M | $19.4B | $1.5B | $470.2M | $361.4M | $386.0M |
| Gross profit | $443.4M | $18.4B | $815.2M | $323.3M | $220.7M | $262.0M |
| Operating income | $215.6M | $17.6B | -$509.0M | -$714.0M | -$505.5M | -$490.1M |
| Net income | $110.4M | $8.1B | $14.5M | -$13.5M | — | — |
| Diluted EPS | $0.97 | $113.44 | $0.20 | -$0.19 | $1.27 | -$0.83 |
| Operating cash flow | $479.3M | $15.3B | -$798.1M | $138.6M | -$56.9M | -$512.2M |
| Free cash flow | $351.8M | $14.7B | -$1.1B | -$17.5M | -$152.9M | -$561.1M |
| Gross margin | 86.8% | 94.9% | 55.3% | 68.8% | 61.1% | 67.9% |
| Operating margin | 42.2% | 91.0% | -34.5% | -151.9% | -139.9% | -127.0% |
| Net margin | 21.6% | 41.9% | 1.0% | -2.9% | — | — |
No quarterly data.
Company news
Apr 23, 2026
Mar 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.